What FVC defines extensive SSc-ILD?

FVC 20% = extensive. FVC ≥70% with HRCT <20% = limited ILD. Extensive disease has higher mortality and progressive fibrosing phenotype.

Which SSc antibodies predict ILD?

Anti-topoisomerase I (Scl-70): high risk of ILD, diffuse SSc. Anti-Th/To: lcSSc with high ILD and PAH risk. Anti-U3-RNP, anti-U11/U12 RNP: also ILD-associated. Anti-centromere: low ILD risk but high PAH risk.

What is the treatment for SSc-ILD?

Mycophenolate mofetil is first-line for SSc-ILD (SLS II trial). Nintedanib (antifibrotic) is approved for progressive fibrosing SSc-ILD regardless of FVC. Tocilizumab may reduce FVC decline in early dcSSc-ILD.

SSc-ILD Baseline Staging and Risk Stratification

Stage and risk-stratify SSc-ILD (systemic sclerosis interstitial lung disease) using FVC% predicted, HRCT extent, and anti-Scl-70 status. Identifies limited vs extensive ILD and guides nintedanib or mycophenolate initiation.

Use the full interactive calculator below, or

Related Calculators

mRSS SSc

Hyper-niche Medical

SSc-ILD Baseline Staging and Risk Stratification

Related Calculators

Frequently Asked Questions

What FVC defines extensive SSc-ILD?

Which SSc antibodies predict ILD?

What is the treatment for SSc-ILD?